Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
ID07139366

Efficacy and Safety of Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment: A Prospective, Multicenter, Randomized Controlled Trial

Led by Yongquan Shi · Updated on 2025-12-02

1248

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness and safety of combining Saccharomyces boulardii with bismuth-containing quadruple therapy compared to the quadruple therapy alone in patients who have not successfully eradicated Helicobacter pylori infection. This Phase 4 trial aims to determine if adding Saccharomyces boulardii improves treatment outcomes for H. pylori rescue therapy. The study has three phases: screening, treatment, and follow-up. During screening, lasting up to 14 days, eligibility is confirmed with tests such as the urea breath test, rapid urease test, or stool antigen test. Participants are randomly assigned to one of two groups for 14 days of treatment: one group receives Saccharomyces boulardii powder alongside standard bismuth, esomeprazole, tetracycline, and furazolidone; the other group receives only the quadruple therapy drugs. Follow-up occurs about 28 days after treatment to confirm H. pylori eradication using the same diagnostic tests. Participants will undergo visits at screening, treatment start, end of treatment, and follow-up. Researchers will monitor eradication success through testing 28 days post-treatment and track any adverse events during treatment and follow-up. The total participation time includes the screening period, 14 days of treatment, and approximately one month of follow-up, ensuring detailed evaluation of therapy outcomes and safety.

CONDITIONS

Brief Title

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 75 years, any gender.
  • Patients with confirmed failure of previous Helicobacter pylori eradication therapies.
  • Women not pregnant or nursing, and if of childbearing potential, must use acceptable contraception during the study and 30 days after.
Not Eligible

You will not qualify if you...

  • Previous use of tetracycline and furazolidone antibiotics for H. pylori infection.
  • Contraindications to study drugs.
  • Severe or unstable heart, lung, or endocrine diseases.
  • Regular use of anti-ulcer drugs, antibiotics, or bismuth complexes shortly before screening.
  • Pregnant or breastfeeding women.
  • History of upper gastrointestinal surgery.
  • Difficulty swallowing.
  • Evidence of bleeding or iron deficiency anemia.
  • History of cancer.
  • Drug or alcohol abuse in the past year.
  • Use of systemic corticosteroids, non-steroidal anti-inflammatory drugs, anticoagulants, or platelet inhibitors (except low-dose aspirin).
  • Mental disorders.
  • Participation in other clinical trials in the past 3 months.
  • Refusal to sign informed consent.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - Up to 2 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for eligibility evaluation and baseline tests including breath, rapid urease, or stool antigen tests

Treatment

Duration - 14 days

Participants receive assigned medication therapy for Helicobacter pylori eradication.

1 randomization visit on Day 0 and 1 end-of-treatment visit between Day 14 and 16

Follow-up

Duration - Approximately 28 days after treatment ends

Participants are assessed for Helicobacter pylori eradication and safety after treatment completion.

1 follow-up visit to confirm eradication using breath, rapid urease, or stool antigen tests

Trial Site Locations

Total: 1 location

1

Xijing Hosipital of Digestive Disease

Xi'an, Shaanxi, China, 710032

Actively Recruiting

Loading map...

Research Team

Y

Yongquan Shi

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Phase III Randomized Controlled Trial Comparing D2 Versus D3...

Gastric Cancer

Actively Recruiting

1 location

Clinical Outcomes of Indocyanine Green Tracer in 3D Plus Ult...

Gastric Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here